Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Merck Sharp & Dohme Corp.
Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
Corifollitropin alfa trial in adult men with hypogonadotropic hypogonadism (HH)
The primary objectives of the trial are: 1) to assess the efficacy of 150 µg MK-8962, given once every two weeks for 52 weeks - in combination with a twice weekly dose of hCG - to increase testicular ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
Sitagliptin with atorvastatin in patients with type 2 diabetes mellitus who have inadequate glycemic control on metformin monotherapy. Szitagliptin és atorvasztatin olyan 2-es típusú diabetes mellitusban szenvedő betegekben vizsgálva, akiknél metformin monoterápia mellett a vércukorszint kontroll nem megfelelő
Objective 1: To assess the effect of sitagliptin in combination with atorvastatin compared to atorvastatin alone on A1C after 16 weeks of treatment. Objective 2: To assess the effect of atorvastatin ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
A Study Comparing MK-8808 to MabThera™ in Patients with Advanced Follicular Lymphoma. Studio di confronto MK-8808 Vs MabThera in Pazienti con linfoma follicolare avanzato
To compare the CR+CRu rate of MK-8808 plus CHOP versus MabThera plus CHOP at week 20 (+/- 1 week) after randomization. Confrontare il tasso di risposte complete (CR) e risposte complete non con...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
Pembrolizumab or placebo in combination with chemoradiation (CRT) in subjects with locally advanced HNSCC
To compare Event-free survival (EFS) per RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 by blinded independent central review (BICR) in subjects treated with pembrolizumab in combination wi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerabitlity, and Efficacy of Telcagepant (MK-0974) for prevention of Menstrually Related Migraine in Female Patients with Episodic Migraine
1. To evaluate the efficacy of telcagepant 140 mg once daily for 7-days per month compared to placebo for the prevention of migraine during the study period in female patients with menstruelly relate...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
Pediatric study to evaluate the appropriate dose for aprepitant in pediatric patients undergoing surgery. Estudio pediatrico para evaluar la dosis apropiada de aprepitant en pacientes pediátricos para la prevención de las náuseas y los vómitos postoperatorios
To estimate post-operative aprepitant plasma concentration profiles and pharmacokinetic parameters by population analysis including historical data (e.g. Cmax, Tmax, AUC0-?, t1/2, CL/F) in Dose 1, 2, ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
Trial 1 to Assess MK-8342B Treatment Efficacy-Safety in Dysmenorrhea plus Extension
1) Objective: To evaluate the efficacy of the ENG-E2 vaginal ring relative to placebo in the treatment of dysmenorrhea at Treatment Cycle 2. 2) Objective: To assess the safety and tolerability of the...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
Pembrolizumab vs Chemotherapy in Microsatellite Instability-High or Mismatch Repair Deficient Stage IV Colorectal Cancer
To compare Progression Free Survival (PFS) per RECIST 1.1 by central imaging vendor in subjects with first line (1L) stage IV MSI-H or dMMR CRC treated with pembrolizumab versus SOC chemotherapies.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
A Phase 3 study in Patients with Type 2 Diabetes Mellitus
To assess the impact of MK-3102 25 mg q.w. on time to confirmed CV outcomes as measured by the time to first event in the CV composite endpoint of CV-related death, nonfatal MI, nonfatal stroke, or un...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
A Study of the Comparative Bioavailability of Two Second-Generation Investigational Pediatric Oral Granule Formulations of MK-1439 Compared to the Adult Formulation
1.To evaluate the comparative bioavailability of the MK-1439 100 mg adult formulation tablets under fasting conditions to MK-1439 100 mg investigational oral pediatric uncoated and coated granules, 0....
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Précédent
5
6
7
8
9
10
11
12
13
14
Suivant